MRK Merck & Company Inc
Company Analysis
Latest News
Merck’s Experimental Eye Drug Meets Trial Goal, but Raises Safety Concerns
Merck said its experimental drug remigromig met its primary goal in the Phase 2b/3 BRUNELLO study for diabetic macular edema (DME), a leading cause of vision...
Halozyme Wins Order Blocking Merck's Injectable Keytruda in Eight European Markets
A Dutch patent court ruled in favor of Halozyme Therapeutics, finding that Merck's subcutaneous (under-the-skin) version of its cancer drug Keytruda infringes...
🔴 Merck is trading 3.06% down today amid Vaxcyte’s positive Phase 3 VAX-31 results
Merck is trading 3.06% lower at $139.88 amid Vaxcyte’s positive Phase 3 results for VAX-31; coverage does not explicitly attribute Merck’s decline to the...
Scotiabank Raises Merck & Co. Price Target to $180
Scotiabank increased its price target for Merck & Co. (MRK) to $180.00 from $155.00. This suggests a potential upside of approximately 22.8%. The firm...
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion
Merck & Co. has signed an exclusive global licensing agreement with Chinese biotech firm SciBrunch Therapeutics for its experimental cancer drug, SPR2015. The...
Merck, Daiichi Sankyo Pull Lung Cancer Filing After FDA Data Setback
Merck and Daiichi Sankyo voluntarily withdrew their U.S. Biologics License Application (BLA) for ifinatamab deruxtecan, an experimental therapy. The...
Merck, Eisai Win FDA Approval for Welireg Combo, Outperforming Standard Care
The U.S. Food and Drug Administration (FDA) approved Merck’s Welireg (belzutifan) in combination with Eisai’s Lenvima (lenvatinib) for adults with advanced...
Merck Eye Drug Remigromig Matches Standard Treatment in Pivotal Study
Merck reported positive topline results from the pivotal Phase 2b/3 BRUNELLO study for remigromig. This investigational treatment targets diabetic macular...
Merck wins Japan approval for Keytruda injection, slashing treatment times
Japan’s Ministry of Health, Labour and Welfare approved Merck’s KEYTRUDA QLEX for subcutaneous injection across all existing indications. The formulation will...
Merck Price Target Raised Significantly by Leerink Partners
Leerink Partners reiterated an "Outperform" rating for Merck & Co. (MRK). The firm increased its 12-month price target for Merck to $161 from $127. This...
Inhibrx Therapy Nearly Doubles Keytruda Response in Head and Neck Cancer
Inhibrx Biosciences reported that its experimental drug, INBRX-106, combined with Merck’s Keytruda outperformed Keytruda alone in a Phase 2 trial. The...
Guggenheim Raises Merck Price Target to $170 on Cancer Drug Optimism
Guggenheim reiterated its "Buy" rating for Merck & Co. The firm raised its price target to $170 from $146. This decision follows increased sales estimates for...
Wells Fargo Raises Merck Target to $170, Citing $5B Heart Drug Potential
Wells Fargo raised its price target for Merck & Co. to $170 from $150. The firm maintained an overweight rating on the shares. This target represents a...
Merck Faces Future Keytruda Competition as Cipla and Qilu Partner for US Biosimilar Launch
India's Cipla and China's Qilu Pharmaceutical announced a partnership for a Keytruda biosimilar in the United States. This creates a new competitive threat for...
🔴 Merck is trading 12% down in after-hours trading with no clear company-specific catalyst
Merck is trading at $132.35, with a -11.50% change and no clear company-specific announcement, earnings release, or regulatory event explaining the after-hours...
🟢 Merck is trading 3.1% up today with no clear new catalyst
Merck is trading at $155.28, up +3.06% (about 3.1%), with no clear new catalyst; recent bullish analyst target increases and positive oncology-trial momentum...
Merck Fails to Block Medicare Price Talks, Judge Rules Participation Voluntary
A federal judge in Washington, D.C. dismissed Merck’s lawsuit challenging the government’s authority to negotiate Medicare drug prices. This ruling upholds a...
🟢 Merck is trading 3.11% up today after cancer vaccine met both Phase 3 endpoints
Merck is trading at $153.63 (+3.11%) after its jointly developed cancer vaccine with Moderna met both Phase 3 melanoma endpoints. - INTerpath-001 showed...
Merck Downgraded by RBC on 'Unprecedented Valuation' Following Stock Rally
RBC Capital downgraded Merck & Co. (MRK) to "Sector Perform" from "Outperform." The firm cited valuation concerns after the stock's recent surge. RBC...
🟢 Merck is trading 10% up today after positive Phase 3 melanoma vaccine results
Merck is trading 10.44% up now at $149.42 after Merck and Moderna announced positive Phase 3 INTerpath-001 results for intismeran combined with Keytruda. -...